JP7764027B2 - 複素環化合物 - Google Patents

複素環化合物

Info

Publication number
JP7764027B2
JP7764027B2 JP2021535473A JP2021535473A JP7764027B2 JP 7764027 B2 JP7764027 B2 JP 7764027B2 JP 2021535473 A JP2021535473 A JP 2021535473A JP 2021535473 A JP2021535473 A JP 2021535473A JP 7764027 B2 JP7764027 B2 JP 7764027B2
Authority
JP
Japan
Prior art keywords
group
methyl
thieno
piperidin
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535473A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021020585A1 (https=
JPWO2021020585A5 (https=
Inventor
祐介 冨成
慶英 遠又
香苗 蒲
直美 北本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fimecs Inc
Original Assignee
Fimecs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fimecs Inc filed Critical Fimecs Inc
Publication of JPWO2021020585A1 publication Critical patent/JPWO2021020585A1/ja
Publication of JPWO2021020585A5 publication Critical patent/JPWO2021020585A5/ja
Priority to JP2025173320A priority Critical patent/JP2026010092A/ja
Application granted granted Critical
Publication of JP7764027B2 publication Critical patent/JP7764027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021535473A 2019-07-31 2020-07-31 複素環化合物 Active JP7764027B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025173320A JP2026010092A (ja) 2019-07-31 2025-10-15 複素環化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019141699 2019-07-31
JP2019141699 2019-07-31
PCT/JP2020/029589 WO2021020585A1 (ja) 2019-07-31 2020-07-31 複素環化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025173320A Division JP2026010092A (ja) 2019-07-31 2025-10-15 複素環化合物

Publications (3)

Publication Number Publication Date
JPWO2021020585A1 JPWO2021020585A1 (https=) 2021-02-04
JPWO2021020585A5 JPWO2021020585A5 (https=) 2023-08-03
JP7764027B2 true JP7764027B2 (ja) 2025-11-05

Family

ID=74228959

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535473A Active JP7764027B2 (ja) 2019-07-31 2020-07-31 複素環化合物
JP2025173320A Pending JP2026010092A (ja) 2019-07-31 2025-10-15 複素環化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025173320A Pending JP2026010092A (ja) 2019-07-31 2025-10-15 複素環化合物

Country Status (4)

Country Link
US (1) US20220402935A1 (https=)
EP (1) EP4006037A4 (https=)
JP (2) JP7764027B2 (https=)
WO (1) WO2021020585A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119630667A (zh) * 2022-07-25 2025-03-14 细胞基因公司 经取代的咪唑并吡嗪化合物作为irak3的配体定向降解剂
WO2024026262A1 (en) * 2022-07-25 2024-02-01 Celgene Corporation Substituted pyrazolyl-pyridinyl compounds as ligand directed degraders of irak3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517559A (ja) 2016-06-10 2019-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規の化合物
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008045905A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
NZ577150A (en) 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
US9271980B2 (en) 2009-08-03 2016-03-01 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
JP2012106958A (ja) 2010-11-18 2012-06-07 Takeda Chem Ind Ltd 複素環化合物
JP2012176934A (ja) 2011-02-03 2012-09-13 Takeda Chem Ind Ltd 複素環化合物
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US9090624B2 (en) 2011-08-04 2015-07-28 Allergan, Inc. Aromatic bycyclic derivatives as CXCR4 receptor modulators
JP5934986B2 (ja) 2011-09-07 2016-06-15 公益財団法人ヒューマンサイエンス振興財団 アポトーシス阻害タンパク質リガンド−エストロゲン受容体リガンドハイブリッド化合物並びにそれを利用したエストロゲン受容体分解誘導剤及び乳癌、子宮頚癌又は卵巣癌の予防及び治療剤
NO2755614T3 (https=) 2012-01-03 2018-03-31
BR112015001830A2 (pt) 2012-08-09 2017-07-04 Hoffmann La Roche composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CA2930030A1 (en) 2012-11-09 2014-05-15 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
CN103242341B (zh) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
JP6899993B2 (ja) 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2020027225A1 (ja) * 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517559A (ja) 2016-06-10 2019-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規の化合物
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AACR Annual Meeting 2019における当社研究成果の発表について [オンライン]，日本，ファイメクス株式会社，2019年02月28日，[検索日 2020.08.31]，インターネット：<URL: https://www.fimecs.com/wordpress/wp-content/uploads/2019
GAMO,K. et al.，Targeted IRAK-M degradation as a novel and efficacious cancer-immunotherapy overcoming innate-driven，American Association for Cancer Research Annual meeting 2019， セッション カテゴリー: Immunology, セッション タイトル: Molecular Mechanisms in the Immune Respons

Also Published As

Publication number Publication date
JPWO2021020585A1 (https=) 2021-02-04
EP4006037A4 (en) 2023-12-13
US20220402935A1 (en) 2022-12-22
EP4006037A1 (en) 2022-06-01
JP2026010092A (ja) 2026-01-21
WO2021020585A1 (ja) 2021-02-04

Similar Documents

Publication Publication Date Title
JP7249950B2 (ja) ヘテロ環化合物
ES2777123T3 (es) Pirazol para el tratamiento de trastornos autoinmunes
US20230117295A1 (en) Nitrogen containing heterocycles as cdk12 inhibitors
JPWO2015137385A1 (ja) ピリダジン化合物
WO2018066545A1 (ja) 複素環化合物
JP2026010092A (ja) 複素環化合物
WO2022023337A1 (en) Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof
WO2022023339A1 (en) Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
CN107848971B (zh) 杂环化合物
CN112533898A (zh) 杂环化合物
US10800754B2 (en) Heterocyclic amide compound
JP2017222626A (ja) 複素環化合物
EP3514149B1 (en) Heterocyclic amide compound
RU2835082C2 (ru) Гетероциклическое соединение
AU2020321513B2 (en) Heterocyclic compound
HK40072079B (zh) 杂环化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251016

R150 Certificate of patent or registration of utility model

Ref document number: 7764027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150